BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28429830)

  • 1. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.
    Zhong X; Ye L; Su T; Xie J; Zhou W; Jiang Y; Jiang L; Ning G; Wang W
    Clin Endocrinol (Oxf); 2017 Aug; 87(2):127-135. PubMed ID: 28429830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas.
    Wang W; Zhong X; Ye L; Qi Y; Su T; Wei Q; Xie J; Jiang L; Jiang Y; Zhou W; Cui B; Ning G
    Clin Endocrinol (Oxf); 2016 Jun; 84(6):822-9. PubMed ID: 26749044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a novel nomogram predicting pseudohypoxia type pheochromocytomas and paragangliomas.
    Wang Y; Liu L; Chen D; Pang Y; Xu X; Liu J; Li M; Guan X
    J Endocrinol Invest; 2023 Jul; 46(7):1361-1371. PubMed ID: 36508127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
    Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
    J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.
    Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D
    J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nomogram for predicting the presence of germline mutations in pheochromocytomas and paragangliomas.
    Su TW; Zhong X; Ye L; Song W; Jiang L; Xie J; Jiang Y; Zhou W; Zhang C; Wu L; Ning G; Wang W
    Endocrine; 2019 Dec; 66(3):666-672. PubMed ID: 31606865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
    Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
    Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Malignant Pheochromocytoma and Paraganglioma.
    Zheng L; Gu Y; Silang J; Wang J; Luo F; Zhang B; Li C; Wang F
    Front Endocrinol (Lausanne); 2021; 12():684668. PubMed ID: 34234744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers.
    Srirangalingam U; Walker L; Khoo B; MacDonald F; Gardner D; Wilkin TJ; Skelly RH; George E; Spooner D; Monson JP; Grossman AB; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):587-96. PubMed ID: 18419787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and internal validation of a novel predictive model for
    Zhou Y; Gao Y; Ma X; Li T; Cui Y; Wang Y; Li M; Zhang D; Tong A
    Front Endocrinol (Lausanne); 2023; 14():1285631. PubMed ID: 38179299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
    Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
    PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Establishment of risk evaluation model of peritoneal metastasis in gastric cancer and its predictive value].
    Zhao J; Zhou R; Zhang Q; Shu P; Li H; Wang X; Shen Z; Liu F; Chen W; Qin J; Sun Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):47-52. PubMed ID: 28105619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical differences between small and large pheochromocytomas and paragangliomas.
    Zhao L; Li Z; Meng X; Fan H; Zhang Z; Zhang Z; Liu Y; Zhou X; Zhu H
    Front Endocrinol (Lausanne); 2023; 14():1087506. PubMed ID: 36967797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Nomogram for Predicting Intraoperative Hemodynamic Instability in Patients With Pheochromocytoma.
    Zhang Z; Ye Y; Yu J; Liao S; Pan W; Guo Y; Jiang S; Luo C; Zheng F
    Front Endocrinol (Lausanne); 2021; 12():787786. PubMed ID: 35069440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic Clues to Succinate Dehydrogenase (SDH) Deficiency in Pheochromocytomas and Paragangliomas.
    Turchini J; Gill AJ
    Am J Surg Pathol; 2020 Mar; 44(3):422-424. PubMed ID: 31789631
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism.
    Xiao L; Jiang Y; Zhang C; Jiang L; Zhou W; Su T; Ning G; Wang W
    Clin Endocrinol (Oxf); 2019 Jun; 90(6):781-788. PubMed ID: 30820995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.